Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference

Rhea-AI Summary

Profound Medical Corp. (NASDAQ:PROF) announced that management will present a business update at the 2022 Jefferies Global Healthcare Conference in New York City on June 9, 2022, at 4:30 p.m. ET. This presentation will be streamed live and archived on their website. The company develops incision-free therapies for tissue ablation, commercializing products like TULSA-PRO^® for prostate procedures and Sonalleve^® for uterine fibroids and pain management. Both technologies are CE marked and have gained various regulatory approvals.

TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2022 Jefferies Global Healthcare Conference in New York City on Thursday, June 9, 2022 at 4:30 p.m. Eastern Time.

The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO^® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO^® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO^® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve^® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve^® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

FAQ

What is the date and time of Profound Medical's presentation at the Jefferies Global Healthcare Conference?

Profound Medical's presentation is scheduled for June 9, 2022, at 4:30 p.m. Eastern Time.

Where can I watch Profound Medical's presentation from the Jefferies Global Healthcare Conference?

The presentation will be broadcast live and archived on Profound Medical's website under the 'Webcasts' section.

What technologies does Profound Medical develop?

Profound Medical develops incision-free therapies, including TULSA-PRO^® for prostate ablation and Sonalleve^® for treating uterine fibroids.

Is TULSA-PRO^® approved for use?

Yes, TULSA-PRO^® is CE marked, Health Canada approved, and cleared by the FDA.

What is the function of Sonalleve^®?

Sonalleve^® is used for the treatment of uterine fibroids and palliative pain management for bone metastases.